Pharmacokinetics of docetaxel, doxorubicin, and cyclophosphamide in combination treatment

被引：0
|
作者：
Cirillo, I
Reyno, L
Gelmon, K
机构：
[1] Aventis Pharmaceut, Bridgewater, NJ USA
[2] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2004年 / 44卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
17
引用
收藏
页码：1189 / 1189
页数：1
相关论文
共 50 条
  • [31] Administrating docetaxel, doxorubicin, and cyclophosphamide as a neoadjuvant treatment may decrease lymphedema risk in breast cancer patients Response
    Hidding, Janine
    van Laarhoven, Hanneke
    SUPPORTIVE CARE IN CANCER, 2018, 26 (06) : 1689 - 1689
  • [32] Changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) in patients with breast cancer
    Janine T. Hidding
    Carien H. G. Beurskens
    Philip J. van der Wees
    Wilmy C. A. M. Bos
    Maria W. G. Nijhuis-van der Sanden
    Hanneke W. M. van Laarhoven
    Supportive Care in Cancer, 2018, 26 : 1383 - 1392
  • [33] LONG TERM COST-EFFECTIVENESS OF DOCETAXEL PLUS CYCLOPHOSPHAMIDE COMPARED TO DOXORUBICIN PLUS CYCLOPHOSPHAMIDE AS ADJUVANT TREATMENT FOR WOMEN WITH OPERABLE BREAST CANCER
    Jackson, D.
    Lee, J. M.
    Adams, J.
    Gordois, A.
    VALUE IN HEALTH, 2009, 12 (07) : A274 - A274
  • [34] Taxotere(TM) (docetaxel, D), doxorubicin (Dx) and cyclophosphamide (CTX) (TAC) in the treatment of metastatic breast cancer (MBC)
    Nabholtz, JM
    Smyllo, M
    Mackey, JR
    Paterson, A
    Noel, D
    AlTwelgerl, T
    Au, D
    Sansregret, E
    Delorme, F
    Riva, A
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 650 - 650
  • [35] Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer:: The GEPARDUO Study of the German Breast Group
    von Minckwitz, G
    Raab, G
    Caputo, A
    Schütte, M
    Hilfrich, F
    Blohmer, JU
    Gerber, B
    Costa, SD
    Merkle, E
    Eidtmann, H
    Lampe, D
    Jackisch, C
    du Bois, A
    Kaufmann, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) : 2676 - 2685
  • [36] Use of Doxorubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy for Breast Cancer
    Livi, L.
    Meattini, I.
    Cardillo, C. De Luca
    Scotti, V.
    Agresti, B.
    Franzese, C.
    Sanchez, L.
    Nori, J.
    Bertocci, S.
    Cassani, S.
    Bianchi, S.
    Cataliotti, L.
    Biti, G.
    JOURNAL OF CHEMOTHERAPY, 2011, 23 (01) : 36 - 39
  • [37] Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel
    Evangelos Briasoulis
    Vasilis Karavasilis
    Eleftheria Tzamakou
    Dimitra Rammou
    Kali Soulti
    Christina Piperidou
    Nicholas Pavlidis
    Cancer Chemotherapy and Pharmacology, 2004, 53 : 452 - 457
  • [38] Weekly docetaxel in combination with doxorubicin for advanced breast cancer.
    Sancho, JF
    Enrech, S
    Menéndez, P
    Méndez, M
    Quiben, R
    López, P
    Casinello, J
    López, JA
    Domínguez, S
    Palomero, MI
    Perez-Manga, G
    ANNALS OF ONCOLOGY, 2000, 11 : 29 - 29
  • [39] Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel
    Briasoulis, E
    Karavasilis, V
    Tzamakou, E
    Rammou, D
    Soulti, K
    Piperidou, C
    Pavlidis, N
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (05) : 452 - 457
  • [40] TAMOXIFEN (T) IN COMBINATION WITH FLUOROURACIL, DOXORUBICIN, AND CYCLOPHOSPHAMIDE (FAC) FOR TREATMENT OF ADVANCED BREAST-CANCER
    SMITH, L
    BUZDAR, A
    LEGHA, S
    HORTOBAGYI, G
    BLUMENSCHEIN, G
    BREAST CANCER RESEARCH AND TREATMENT, 1984, 4 (04) : 350 - 350
12345